The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Blood

• Publication date

  2006-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2005-10-4025PMID 16484585PMCID PMC1895805
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak.

  2005cited by this paper
• An isoform of the Wilms' tumor suppressor gene potentiates granulocytic differentiation

  2003cited by this paper
• Cyclin E Is a Target of WT1 Transcriptional Repression*

  2002cited by this paper
• Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation.

  2001cited by this paper
• Functional characterization of WT1 binding sites within the human vitamin D receptor gene promoter.

  2001cited by this paper
• The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun

  1999cited by this paper
• The Wilms’ Tumor Suppressor Gene (wt1) Product Regulates Dax-1 Gene Expression during Gonadal Differentiation

  1999cited by this paper
• Ornithine decarboxylase is a transcriptional target of tumor suppressor WT1.

  1999cited by this paper
• WT1 modulates apoptosis by transcriptionally upregulating the bcl‐2 proto‐oncogene

  1999cited by this paper
• Induction of Rb-associated Protein (RbAp46) by Wilms’ Tumor Suppressor WT1 Mediates Growth Inhibition*

  1998cited by this paper
• WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes.

  1998cited by this paper
• Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance.

  1998cited by this paper
• Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/-KTS splice isoforms.

  1998cited by this paper
• Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells.

  1998cited by this paper
• Differential effects of Wilms tumor WT1 splice variants on the insulin receptor promoter.

  1997cited by this paper
• Donor splice-site mutations in WT1 are responsible for Frasier syndrome

  1997cited by this paper
• The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro.

  1997cited by this paper
• Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis.

  1997cited by this paper
• The WT1 Protein Is a Negative Regulator of the Normalbcl-2 Allele in t(14;18) Lymphomas*

  1997cited by this paper
• High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.

  1997cited by this paper
• A1, a Bcl-2 family member, prolongs cell survival and permits myeloid differentiation.

  1996cited by this paper
• Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing.

  1995cited by this paper
• Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.

  1995cited by this paper
• WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.

  1994cited by this paper
• WT-1 is required for early kidney development.

  1993cited by this paper
• Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2.

  1993cited by this paper
• A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1.

  1993cited by this paper
• Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1.

  1992cited by this paper
• Alternative splicing and genomic structure of the Wilms tumor gene WT1.

  1991cited by this paper
• Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus.

  1990cited by this paper
• Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping

  1990cited by this paper

• WT1 gene: a potential therapeutic target for multiple cancer treatment strategies

  2025cites this paper
• Contribution of A1 to macrophage survival in cooperation with MCL-1 and BCL-XL in a murine cell model of myeloid differentiation

  2024cites this paper
• COX2-Inhibitory and Cytotoxic Activities of Phytoconstituents of Matricaria chamomilla L.

  2023cites this paper
• Mitigating the Bfl-1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs

  2022cites this paper
• First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience

  2022cites this paper
• Last but not least: BFL-1 as an emerging target for anti-cancer therapies

  2022cites this paper
• Construction of three‐gene‐based prognostic signature and analysis of immune cells infiltration in children and young adults with B‐acute lymphoblastic leukemia

  2022influential citation
• Stayin' alive: BCL-2 proteins in the hematopoietic system.

  2022cites this paper
• Truncated WT1 Protein Isoform Expression Is Increased in MCF-7 Cells with Long-Term Estrogen Depletion

  2021cites this paper
• Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy.

  2021cites this paper
• Truncated WT1 protein isoform expression is increased in MCF-7 cells in a long-term estrogen depletion

  2019cites this paper
• Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.

  2019cites this paper
• Développement d’un modèle murin syngénique et immun de leucémie aiguë myéloïde et de maladie résiduelle mesurable surexprimant ou non le gène Wilms Tumor 1

  2018cites this paper
• DNA and RNA binding by the Wilms' tumour gene 1 (WT1) protein +KTS and −KTS isoforms—From initial observations to recent global genomic analyses

  2018cites this paper
• Loss of Wilms tumor 1 protein is a marker for apoptosis in response to replicative stress in leukemic cells

  2018influential citation
• P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB)

  2018cites this paper
• Synthetic CpG oligonucleotides induce a genetic profile ameliorating murine myocardial I/R injury

  2018cites this paper
• Loss of Wilms tumor 1 protein is a marker for apoptosis in response to replicative stress in leukemic cells

  2018influential citation
• Régulation de la stabilité de la protéine anti-apoptotique BCL2A1

  2018cites this paper
• The Complex Role of the ZNF224 Transcription Factor in Cancer.

  2017cites this paper
• the antimetabolite cytarabine in leukemic cells involving the zinc finger protein ZNF 224 , acting as a cofactor of the Wilms ' tumor gene 1 ( WT 1 ) protein

  2017cites this paper
• WT1 Alternative Splicing: Role of Its Isoforms in Neuroblastoma

  2017cites this paper
• Clinical Impact of Overexpression of FOXP3 and WT1 on Disease Outcome in Egyptian Acute Myeloid Leukemia Patients

  2016cites this paper
• Bcl‐2 proteins in development, health, and disease of the hematopoietic system

  2016cites this paper
• Significance of Wilms’ tumor gene 1 as a biomarker in acute leukemia and solid tumors

  2016cites this paper
• The hematopoietic tumor suppressor interferon regulatory factor 8 (IRF8) is upregulated by the antimetabolite cytarabine in leukemic cells involving the zinc finger protein ZNF224, acting as a cofactor of the Wilms' tumor gene 1 (WT1) protein.

  2016cites this paper
• Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms

  2015cites this paper
• WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene

  2015cites this paper
• Wilms' tumor gene 1 in different types of cancer

  2015cites this paper
• Inhibition des protéines anti-apoptotiques de la famille Bcl-2 par l'ABT-737 : intérêt pour le traitement des cancers des voies aérodigestives supérieures

  2015cites this paper
• WT1 role in mammary gland and breast cancer biology

  2015cites this paper
• Nutlin-3 induces BCL2A1 expression by activating ELK1 through the mitochondrial p53-ROS-ERK1/2 pathway.

  2014cites this paper
• Mechanisms of transcriptional regulation by WT1 (Wilms' tumour 1).

  2014influential citation
• Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells

  2014cites this paper
• Role of WT1-ZNF224 interaction in the expression of apoptosis-regulating genes.

  2013influential citation
• Etiological and clinical studies of Langerhans Cell Histiocytosis (LCH)

  2013cites this paper
• Antiapoptotic Proteins in Human Macrophage Survival, Differentiation, Innate Immunity and Protection from HIV-induced Apoptosis

  2013cites this paper
• Detektion spezifischer T-Zellantworten gegen die Mitose-assoziierten Antigene Survivin und Aurorakinase bei der AML

  2012cites this paper
• A1/Bfl-1 in leukocyte development and cell death

  2012cites this paper
• Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia

  2012cites this paper
• The Transcription Factor Wilms Tumor 1 Confers Resistance in Myeloid Leukemia Cells against the Proapoptotic Therapeutic Agent TRAIL (Tumor Necrosis Factor α-related Apoptosis-inducing Ligand) by Regulating the Antiapoptotic Protein Bcl-xL*

  2012cites this paper
• DYSREGULATION OF MEOX2 FOLLOWING WT1 MUTATION IN KIDNEY DEVELOPMENT AND WILMS TUMORIGENESIS

  2011cites this paper
• T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.

  2011cites this paper
• Characterisation and manipulation of docetaxel resistant prostate cancer cell lines

  2011cites this paper
• Tumour-associated antigens: considerations for their use in tumour immunotherapy

  2011cites this paper
• BCL2A1: the underdog in the BCL2 family

  2011cites this paper
• Wilms’ tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression

  2011cites this paper
• Deregulated expression of A1, Bcl-2, Bcl-xL, and Mcl-1 antiapoptotic proteins and Bid, Bad, and Bax proapoptotic genes in polycythemia vera patients

  2011cites this paper
• WT1 Protein Directly Regulates Expression of Vascular Endothelial Growth Factor and Is a Mediator of Tumor Response to Hypoxia*

  2011cites this paper
• AN EFFECTOR IN LEUKEMOGENESIS

  2010cites this paper
• Characterisation in mice of a conserved sequence, Mcr2, associated with the Wilms' tumour 1 (Wt1) locus

  2010cites this paper
• TO WILMS TUMOR PROTEIN ( WT 1 ) IN MYELODYSPLASIA RESPONSIVE TO IMMUNOSUPPRESSIVE THERAPY ( IST )

  2010cites this paper
• Anti-apoptotic function of T-KTS+, T-KTS-, WT1+/+ and WT1+/- isoforms in breast cancer

  2010cites this paper
• WILMS’ TUMOUR GENE 1 PROTEIN (WT1) – AN EFFECTOR IN LEUKEMOGENESIS?

  2010cites this paper
• The Wilms' Tumor Suppressor Protein WT1 Is Processed by the Serine Protease HtrA2/Omi

  2010cites this paper
• HtrA2, taming the oncogenic activities of WT1

  2010cites this paper
• Mitochondrial membrane potential in human neutrophils is maintained by complex III activity in the absence of supercomplex organisation

  2009cites this paper
• WT1 Induction of Mitogen-Activated Protein Kinase Phosphatase 3 Represents a Novel Mechanism of Growth Suppression

  2008cites this paper
• Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells

  2008cites this paper
• Regulation of mast cell survival and apoptosis

  2008cites this paper
• survival gene A 1 following IgE receptor activation in mast cells B is critical for transcriptional induction of the κ NFAT but

  2008cites this paper
• NFAT but not NF-kappaB is critical for transcriptional induction of the prosurvival gene A1 after IgE receptor activation in mast cells.

  2008cites this paper
• A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis.

  2007cites this paper
• The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis

  2007cites this paper
• Molecular mechanisms of drug resistance in acute myeloid leukaemia

  2007cites this paper
• Utan tvivel är man inte klok

  2006cites this paper
• The Expression and Function of Wilms' Tumor 1 in Malignant Glioma

  2006cites this paper
• WT1 Influences Apoptosis Through Transcriptional Regulation of Bcl-2 Family Members

  2006cites this paper